Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) was the target of a significant decrease in short interest in October. As of October 30th, there was short interest totaling 9,125 shares, a decrease of 49.8% from the October 15th total of 18,161 shares. Based on an average trading volume of 8,875 shares, the short-interest ratio is presently 1.0 days. Currently, 0.0% of the shares of the company are short sold.
Analyst Ratings Changes
AAPG has been the subject of several analyst reports. Citigroup started coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, October 14th. They issued a “buy” rating and a $46.00 price objective for the company. Citizens Jmp assumed coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 target price on the stock. BTIG Research restated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. JPMorgan Chase & Co. lowered their target price on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a report on Thursday, October 8th. Finally, William Blair started coverage on shares of Ascentage Pharma Group International in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating and eleven have given a Buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $43.44.
Check Out Our Latest Research Report on AAPG
Ascentage Pharma Group International Price Performance
Shares of NASDAQ:AAPG opened at $14.62 on Monday. The firm has a 50 day moving average of $15.36 and a 200-day moving average of $19.61. Ascentage Pharma Group International has a 12 month low of $13.46 and a 12 month high of $34.50. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22.
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million for the quarter. As a group, equities research analysts expect that Ascentage Pharma Group International will post -2.43 EPS for the current year.
About Ascentage Pharma Group International
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
See Also
- Five stocks we like better than Ascentage Pharma Group International
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
